Bill Gates Backs NYC's Robot Revolution: Opentrons AI Changing Science And Medicine With Robot Pricing Starting At $10,000

Opentrons, a Long Island City-based biotech company, is at the forefront of the robot revolution. Known for its cutting-edge AI-powered robots, Opentrons is revolutionizing scientific research, particularly in health care. Backed by prominent investors like Bill Gates, the company is dramatically reducing costs in the biotech space by automating complex lab procedures, making science more accessible and efficient.

Don't Miss:

• Don’t miss the real AI boom – here’s how to use just $10 to invest in high growth private tech companies.
• Unlock a $400 billion opportunity by investing in the future of EV infrastructure on this startup already valued at $50 million with just $500.

Bill Gates has long been an advocate for global health initiatives. He donates heavily to fund Alzheimer's research and the Bill and Melinda Gates Foundation also heads the fight against malaria to eradicate the disease. So, it's no surprise that Gates is backing this innovative tech company. 

Gates' involvement with Opentrons takes them one step closer to fulfilling their mission to make advanced technology accessible to scientists worldwide. According to the New York Post, Gates helped connect the company to rural African villages that needed the tech devices. 

Trending: Teens may never need wisdom teeth removed thanks to this MedTech Company – Be an early investor for just $300 for 100 shares!

Jonathan Brennan-Badal, Opentrons' CEO, shared Gates' vision during an interview with The Post, saying, "His principle interest really is around how we can be building a platform and ecosystem … enabling third-party developers like other startups, scientists to build new applications for our robot, build new devices, hardware devices that can integrate with our platform."

Opentrons has integrated AI tools like ChatGPT and large language models (LLM) into their robots to simplify the programming process. This allows scientists to use simple prompts, like "run a COVID test," without requiring extensive coding knowledge to get the robot to work. Once the prompt is said, the robot takes care of the rest. 

These robots are saving scientists time and money worldwide. They are already deployed in 14 of the 15 leading global pharmaceutical companies, performing tasks such as sequencing DNA and intricate lab tests. They are transforming how scientists conduct their research. 

Trending: This Jeff Bezos-backed startup will allow you to become a landlord in just 10 minutes, and you only need $100.

On the topic of saving money, Opentrons' robots played a significant role during the COVID-19 pandemic. The company set up a Pandemic Response Lab (PRL) in 2020 and used 40 of its robots to conduct over 12 million COVID tests in New York City. This automation saved the city and taxpayers roughly 80% of the cost, approximating around $600 billion in savings. These robots were also the first to identify new variants of COVID-19, including Omicron. 

Beyond the cost savings to taxpayers and scientists, the price point for Opentrons robots is also appealing. The robots start at $10,000, significantly more affordable than leading competitors, who charge around $100,000. 

Trending: Will the surge continue or decline on real estate prices? People are finding out about risk-free real estate investing that lets you cash out whenever you want.

A more affordable robot like this allows smaller labs and research facilities to access this advanced technology worldwide. Opentrons' mission goes beyond just making a more affordable solution though. It's important that their robots are portable too. Their robots have been used in remote locations – and can even run on car batteries – to test for disease outbreaks. 

Opentrons' innovation doesn't stop at testing. The company is working on reducing the astronomical costs of gene therapy, which currently exceeds $1 million per treatment. By leveraging robotics and automation, Opentrons aims to reduce these costs to $30,000 or less, making lifesaving treatments accessible to a broader population.

Read Next:

• Founder of Personal Capital and ex-CEO of PayPal re-engineers traditional banking with this new high-yield account — start saving better today.
• These five entrepreneurs are worth $223 billion – they all believe in one platform that offers a 7-9% target yield with monthly dividends